Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours
Open Access
- 28 June 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 105 (2), 246-254
- https://doi.org/10.1038/bjc.2011.197
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJama-Journal Of The American Medical Association, 2010
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicineBritish Journal of Cancer, 2010
- Signal integration by JNK and p38 MAPK pathways in cancer developmentNature Reviews Cancer, 2009
- Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissuesAnalytical Biochemistry, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- Mutations of the BRAF gene in human cancerNature, 2002
- Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ studyBritish Journal of Cancer, 2001
- Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutationEuropean Journal of Cancer, 2000